JP2024517741A5 - - Google Patents
Info
- Publication number
- JP2024517741A5 JP2024517741A5 JP2023566501A JP2023566501A JP2024517741A5 JP 2024517741 A5 JP2024517741 A5 JP 2024517741A5 JP 2023566501 A JP2023566501 A JP 2023566501A JP 2023566501 A JP2023566501 A JP 2023566501A JP 2024517741 A5 JP2024517741 A5 JP 2024517741A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- amino acid
- acid sequences
- lcdr1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163183635P | 2021-05-04 | 2021-05-04 | |
| US63/183,635 | 2021-05-04 | ||
| PCT/IL2022/050453 WO2022234571A2 (en) | 2021-05-04 | 2022-05-02 | Anti-nkg2d antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517741A JP2024517741A (ja) | 2024-04-23 |
| JP2024517741A5 true JP2024517741A5 (enExample) | 2025-04-16 |
Family
ID=83932629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023566501A Pending JP2024517741A (ja) | 2021-05-04 | 2022-05-02 | 抗ｎｋｇ２ｄ抗体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240228626A1 (enExample) |
| EP (1) | EP4333889A4 (enExample) |
| JP (1) | JP2024517741A (enExample) |
| KR (1) | KR20240004838A (enExample) |
| CN (1) | CN117396220A (enExample) |
| AU (1) | AU2022269411A1 (enExample) |
| BR (1) | BR112023023090A2 (enExample) |
| CA (1) | CA3217726A1 (enExample) |
| IL (1) | IL308204A (enExample) |
| MX (1) | MX2023013017A (enExample) |
| WO (1) | WO2022234571A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116199777B (zh) * | 2021-12-01 | 2025-01-28 | 北京免疫方舟医药科技有限公司 | 抗hNKG2D抗体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009077483A1 (en) * | 2007-12-14 | 2009-06-25 | Novo Nordisk A/S | Antibodies against human nkg2d and uses thereof |
| US9273136B2 (en) * | 2008-08-04 | 2016-03-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fully human anti-human NKG2D monoclonal antibodies |
| CN105777907B (zh) * | 2010-02-24 | 2020-03-17 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| EP2995679A4 (en) * | 2013-03-11 | 2016-12-14 | Kansai Bunri Sogo Gakuen | PROCESS FOR PREPARING MONOCLONAL IGA ANTIBODIES |
| US20170145086A1 (en) * | 2015-11-25 | 2017-05-25 | Visterra, Inc. | Antibody molecules to april and uses thereof |
| WO2018030405A1 (ja) * | 2016-08-09 | 2018-02-15 | 国立大学法人東京医科歯科大学 | Ｈｍｇｂ１に対する抗体、及びそれを含有するアルツハイマー病を治療又は予防するための組成物 |
| CN113811549A (zh) * | 2019-02-21 | 2021-12-17 | Xencor股份有限公司 | 非靶向和靶向性il-10 fc融合蛋白 |
| CN113811546B (zh) * | 2019-05-07 | 2025-03-11 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
| AR119393A1 (es) * | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
| US20210024644A1 (en) * | 2019-07-25 | 2021-01-28 | Zomedica Pharmaceuticals Corp. | N-cadherin binding molecules and uses thereof |
| CN116096754A (zh) * | 2020-05-04 | 2023-05-09 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
-
2022
- 2022-05-02 US US18/558,679 patent/US20240228626A1/en active Pending
- 2022-05-02 IL IL308204A patent/IL308204A/en unknown
- 2022-05-02 JP JP2023566501A patent/JP2024517741A/ja active Pending
- 2022-05-02 MX MX2023013017A patent/MX2023013017A/es unknown
- 2022-05-02 AU AU2022269411A patent/AU2022269411A1/en not_active Abandoned
- 2022-05-02 EP EP22798772.4A patent/EP4333889A4/en active Pending
- 2022-05-02 KR KR1020237041484A patent/KR20240004838A/ko active Pending
- 2022-05-02 CA CA3217726A patent/CA3217726A1/en active Pending
- 2022-05-02 BR BR112023023090A patent/BR112023023090A2/pt unknown
- 2022-05-02 CN CN202280032427.2A patent/CN117396220A/zh active Pending
- 2022-05-02 WO PCT/IL2022/050453 patent/WO2022234571A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022177090A5 (enExample) | ||
| JP2023002562A5 (enExample) | ||
| JP2021521843A5 (enExample) | ||
| JP2024109678A5 (enExample) | ||
| JP2020528768A5 (enExample) | ||
| JP2022533538A5 (enExample) | ||
| JP2023093753A5 (enExample) | ||
| JP2024540148A5 (enExample) | ||
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| JP2020522280A5 (enExample) | ||
| JP2006502699A5 (enExample) | ||
| JP2020522281A5 (enExample) | ||
| JP2025183307A5 (enExample) | ||
| JP2025501775A5 (enExample) | ||
| JP2012532851A5 (enExample) | ||
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение | |
| JP2023516195A5 (enExample) | ||
| JP2024024114A5 (enExample) | ||
| JP2021512652A5 (enExample) | ||
| CN111712521A (zh) | Cd38蛋白抗体及其应用 | |
| JP2022517216A5 (enExample) | ||
| JP2023509373A5 (enExample) | ||
| JP2023506834A5 (enExample) | ||
| JP2022519631A5 (enExample) | ||
| JP2024517760A5 (enExample) |